<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Plasma Cell | Clinical Hematology</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="2.1 Overview of Plasma Cell Dyscrasias  Definition: A group of disorders characterized by the abnormal proliferation of a single clone of plasma cells, leading to the overproduction of a...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="Plasma Cell | Clinical Hematology">
<meta property="og:type" content="book">
<meta property="og:description" content="2.1 Overview of Plasma Cell Dyscrasias  Definition: A group of disorders characterized by the abnormal proliferation of a single clone of plasma cells, leading to the overproduction of a...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Plasma Cell | Clinical Hematology">
<meta name="twitter:description" content="2.1 Overview of Plasma Cell Dyscrasias  Definition: A group of disorders characterized by the abnormal proliferation of a single clone of plasma cells, leading to the overproduction of a...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Clinical Hematology</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li class="book-part">Erythrocytes</li>
<li><a class="" href="rbc-production.html">RBC Production</a></li>
<li><a class="" href="rbc-function.html">RBC Function</a></li>
<li><a class="" href="rbc-destruction.html">RBC Destruction</a></li>
<li><a class="" href="anemais.html">Anemais</a></li>
<li><a class="" href="microcytic.html">Microcytic</a></li>
<li><a class="" href="iron-deficiency.html">Iron Deficiency</a></li>
<li><a class="" href="chronic-disease.html">Chronic Disease</a></li>
<li><a class="" href="thalassemias.html">Thalassemias</a></li>
<li><a class="" href="sideroblastic.html">Sideroblastic</a></li>
<li><a class="" href="porphyria.html">Porphyria</a></li>
<li><a class="" href="normocytic.html">Normocytic</a></li>
<li><a class="" href="hereditary-hemolytic.html">Hereditary Hemolytic</a></li>
<li><a class="" href="acquired-hemolytic.html">Acquired Hemolytic</a></li>
<li><a class="" href="hypoproliferative.html">Hypoproliferative</a></li>
<li><a class="" href="acute-hemorrhage.html">Acute Hemorrhage</a></li>
<li><a class="" href="macrocytic.html">Macrocytic</a></li>
<li><a class="" href="megaloblastic.html">Megaloblastic</a></li>
<li><a class="" href="nonmegaloblastic.html">Nonmegaloblastic</a></li>
<li><a class="" href="hemoglobinopathies.html">Hemoglobinopathies</a></li>
<li><a class="" href="erythrocytosis.html">Erythrocytosis</a></li>
<li class="book-part">Leukocytes</li>
<li><a class="" href="wbc-production.html">WBC Production</a></li>
<li><a class="" href="wbc-function.html">WBC Function</a></li>
<li><a class="" href="wbc-destruction.html">WBC Destruction</a></li>
<li><a class="" href="benign-disorders.html">Benign Disorders</a></li>
<li><a class="" href="myeloid.html">Myeloid</a></li>
<li><a class="" href="lymphoid.html">Lymphoid</a></li>
<li><a class="" href="myeloid-neoplasia.html">Myeloid Neoplasia</a></li>
<li><a class="" href="aml.html">AML</a></li>
<li><a class="" href="myelodysplastic.html">Myelodysplastic</a></li>
<li><a class="" href="myeloproliferative.html">Myeloproliferative</a></li>
<li><a class="" href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></li>
<li><a class="" href="acute-lymphoid.html">Acute Lymphoid</a></li>
<li><a class="" href="chronic-b-cell.html">Chronic B-Cell</a></li>
<li><a class="" href="chronic-t-cell.html">Chronic T-Cell</a></li>
<li><a class="active" href="plasma-cell.html">Plasma Cell</a></li>
<li class="book-part">Platelets</li>
<li><a class="" href="plt-production.html">PLT Production</a></li>
<li><a class="" href="plt-function.html">PLT Function</a></li>
<li><a class="" href="plt-destruction.html">PLT Destruction</a></li>
<li><a class="" href="quantitative.html">Quantitative</a></li>
<li><a class="" href="thrombocytopenia-1.html">Thrombocytopenia</a></li>
<li><a class="" href="destruction.html">Destruction</a></li>
<li><a class="" href="production.html">Production</a></li>
<li><a class="" href="pseudo.html">Pseudo</a></li>
<li><a class="" href="thrombocytosis.html">Thrombocytosis</a></li>
<li><a class="" href="qualitative.html">Qualitative</a></li>
<li><a class="" href="von-willebrand.html">von Willebrand</a></li>
<li><a class="" href="bernard-soulier.html">Bernard-Soulier</a></li>
<li><a class="" href="glanzmann.html">Glanzmann</a></li>
<li class="book-part">Hemostasis</li>
<li><a class="" href="coagulation-pathways.html">Coagulation Pathways</a></li>
<li><a class="" href="fibrinolytic-pathways.html">Fibrinolytic Pathways</a></li>
<li><a class="" href="vascular-system.html">Vascular System</a></li>
<li><a class="" href="disorders.html">Disorders</a></li>
<li><a class="" href="factor-deficiencies.html">Factor Deficiencies</a></li>
<li><a class="" href="hereditary.html">Hereditary</a></li>
<li><a class="" href="acquired.html">Acquired</a></li>
<li><a class="" href="inhibitors.html">Inhibitors</a></li>
<li><a class="" href="fibrinolytic.html">Fibrinolytic</a></li>
<li><a class="" href="thrombophilia.html">Thrombophilia</a></li>
<li><a class="" href="dic.html">DIC</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Hematology">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="plasma-cell" class="section level1 unnumbered">
<h1>Plasma Cell<a class="anchor" aria-label="anchor" href="#plasma-cell"><i class="fas fa-link"></i></a>
</h1>
<div id="overview-of-plasma-cell-dyscrasias" class="section level2" number="2.1">
<h2>
<span class="header-section-number">2.1</span> <strong>Overview of Plasma Cell Dyscrasias</strong><a class="anchor" aria-label="anchor" href="#overview-of-plasma-cell-dyscrasias"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A group of disorders characterized by the abnormal proliferation of a single clone of plasma cells, leading to the overproduction of a monoclonal immunoglobulin (M protein)</li>
<li>
<strong>Synonyms:</strong> Monoclonal Gammopathies, Plasma Cell Disorders</li>
<li>
<strong>Key Features:</strong>
<ul>
<li>Monoclonal Gammopathy: The presence of a monoclonal immunoglobulin (M protein) in the serum or urine. The M protein is produced by the abnormal clone of plasma cells</li>
<li>Bone Marrow Involvement: The bone marrow is often infiltrated by the clonal plasma cells</li>
<li>Organ Damage: May lead to organ damage due to M protein deposition, bone lesions, hypercalcemia, renal dysfunction, and increased susceptibility to infections</li>
</ul>
</li>
<li>
<strong>Spectrum of Disorders:</strong> Range from benign to malignant:
<ul>
<li>Monoclonal Gammopathy of Undetermined Significance (MGUS): Benign condition with low levels of M protein and no evidence of end-organ damage</li>
<li>Smoldering Multiple Myeloma (SMM): Intermediate condition with higher levels of M protein but still no end-organ damage</li>
<li>Multiple Myeloma (MM): Malignant plasma cell disorder with M protein, bone marrow involvement, and end-organ damage</li>
<li>Waldenström Macroglobulinemia (WM): A lymphoplasmacytic lymphoma that produces IgM M protein (covered in the previous study guide)</li>
<li>Other Plasma Cell Dyscrasias: Rare disorders such as heavy chain diseases and plasma cell leukemia</li>
</ul>
</li>
</ul>
</div>
<div id="multiple-myeloma-mm" class="section level2 unnumbered">
<h2>
<strong>Multiple Myeloma (MM)</strong><a class="anchor" aria-label="anchor" href="#multiple-myeloma-mm"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A malignant plasma cell disorder characterized by the clonal proliferation of plasma cells in the bone marrow, leading to the overproduction of a monoclonal immunoglobulin (M protein) and associated end-organ damage</li>
<li>
<strong>Diagnostic Criteria:</strong>
<ul>
<li>Clonal Bone Marrow Plasma Cells ≥10% or Biopsy-Proven Extramedullary Plasmacytoma</li>
<li>Presence of M Protein in Serum and/or Urine (except in rare cases of nonsecretory myeloma)</li>
<li>Evidence of End-Organ Damage (CRAB Criteria):
<ul>
<li>Hypercalcemia: Elevated serum calcium level</li>
<li>Renal Insufficiency: Elevated creatinine or decreased glomerular filtration rate (GFR)</li>
<li>Anemia: Low hemoglobin level</li>
<li>Bone Lesions: Lytic lesions, fractures, or osteopenia on skeletal survey or imaging studies</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Clonal Plasma Cell Proliferation: Abnormal plasma cells accumulate in the bone marrow, disrupting normal hematopoiesis</li>
<li>M Protein Production: Excessive production of a monoclonal immunoglobulin (IgG, IgA, IgD, or IgE) or light chains (kappa or lambda)</li>
<li>Bone Destruction: Myeloma cells secrete factors that stimulate osteoclast activity, leading to bone resorption and lytic lesions</li>
<li>Immunosuppression: Myeloma cells suppress the normal immune system, increasing susceptibility to infections</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Bone Pain: Most common symptom</li>
<li>Fatigue and Weakness: Due to anemia</li>
<li>Pathologic Fractures: Fractures that occur with minimal trauma due to weakened bones</li>
<li>Recurrent Infections: Due to immunosuppression</li>
<li>Renal Insufficiency: Due to M protein deposition in the kidneys (myeloma cast nephropathy)</li>
<li>Hypercalcemia: Can cause confusion, constipation, and kidney damage</li>
<li>Neurological Symptoms: Due to spinal cord compression or hyperviscosity syndrome</li>
<li>Amyloidosis: Deposition of light chains in tissues, causing organ damage</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC:
<ul>
<li>Anemia (normocytic or normochromic)</li>
<li>Thrombocytopenia</li>
<li>Leukopenia (less common)</li>
<li>Rouleaux formation: Stacking of RBCs due to increased serum protein</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>Normal or abnormal RBC morphology</li>
<li>May see plasma cells or circulating myeloma cells (rare)</li>
</ul>
</li>
<li>Serum Protein Electrophoresis (SPEP):
<ul>
<li>Monoclonal spike (M protein) in the gamma region (usually IgG or IgA)</li>
</ul>
</li>
<li>Serum Immunofixation Electrophoresis (IFE):
<ul>
<li>Confirms the presence and type of M protein (IgG kappa, IgA lambda, etc.)</li>
</ul>
</li>
<li>Serum Free Light Chain (FLC) Assay:
<ul>
<li>Measures free kappa and lambda light chains in the serum</li>
<li>Increased FLC ratio (kappa/lambda or lambda/kappa) is common</li>
</ul>
</li>
<li>Urine Protein Electrophoresis (UPEP) and Immunofixation:
<ul>
<li>May detect Bence Jones protein (free light chains) in the urine</li>
</ul>
</li>
<li>Serum Beta-2 Microglobulin:
<ul>
<li>Elevated levels indicate increased tumor burden</li>
<li>Used for staging and prognosis</li>
</ul>
</li>
<li>Serum Albumin:
<ul>
<li>Decreased levels are associated with poorer prognosis</li>
</ul>
</li>
<li>Serum Calcium:
<ul>
<li>Elevated in hypercalcemia</li>
</ul>
</li>
<li>Renal Function Tests:
<ul>
<li>Elevated creatinine and decreased GFR in renal insufficiency</li>
</ul>
</li>
<li>Skeletal Survey (X-rays):
<ul>
<li>Lytic lesions (“punched-out” lesions) in bones</li>
<li>Osteopenia</li>
<li>Fractures</li>
</ul>
</li>
<li>Bone Marrow Aspiration and Biopsy:
<ul>
<li>Increased plasma cells (≥10%)</li>
<li>Abnormal plasma cell morphology</li>
<li>Immunohistochemistry: To identify plasma cell markers (CD138, CD56)</li>
</ul>
</li>
<li>Cytogenetic Analysis:
<ul>
<li>Karyotyping and FISH (fluorescence in situ hybridization)</li>
<li>Detect chromosomal abnormalities that are used for prognosis and risk stratification (e.g., del(17p), t(4;14), t(14;16))</li>
</ul>
</li>
<li>Molecular Testing:
<ul>
<li>To detect gene mutations that are used for prognosis (e.g., <em>TP53</em>, <em>BRAF</em>)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Staging:</strong>
<ul>
<li>Revised International Staging System (R-ISS):
<ul>
<li>Used to determine treatment and outcomes.</li>
<li>Serum beta2-microglobulin level</li>
<li>Serum albumin level</li>
<li>Cytogenetic abnormalities (detected by FISH)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Treatment depends on risk assessment and patient fitness</li>
<li>Proteasome Inhibitors:
<ul>
<li>Bortezomib, carfilzomib, ixazomib</li>
</ul>
</li>
<li>Immunomodulatory Drugs (IMiDs):
<ul>
<li>Lenalidomide, thalidomide, pomalidomide</li>
</ul>
</li>
<li>Monoclonal Antibodies:
<ul>
<li>Daratumumab (anti-CD38)</li>
<li>Elotuzumab (anti-SLAMF7)</li>
</ul>
</li>
<li>Chemotherapy:
<ul>
<li>Alkylating agents (e.g., melphalan, cyclophosphamide)</li>
</ul>
</li>
<li>Corticosteroids:
<ul>
<li>Dexamethasone, prednisone</li>
</ul>
</li>
<li>Autologous Hematopoietic Stem Cell Transplantation (ASCT):
<ul>
<li>A standard treatment for eligible patients</li>
</ul>
</li>
<li>CAR T-Cell Therapy:
<ul>
<li>Used for relapsed/refractory myeloma</li>
</ul>
</li>
<li>Bispecific Antibodies:
<ul>
<li>Emerging therapies that bind to both CD3 on T cells and BCMA on myeloma cells, bringing them together to kill the myeloma cells</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="monoclonal-gammopathy-of-undetermined-significance-mgus" class="section level2 unnumbered">
<h2>
<strong>Monoclonal Gammopathy of Undetermined Significance (MGUS)</strong><a class="anchor" aria-label="anchor" href="#monoclonal-gammopathy-of-undetermined-significance-mgus"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A benign condition characterized by the presence of a monoclonal immunoglobulin (M protein) in the serum or urine, <em>without</em> evidence of end-organ damage or other features of multiple myeloma, Waldenström macroglobulinemia, or other lymphoid disorders</li>
<li>
<strong>Diagnostic Criteria:</strong>
<ul>
<li>Serum M protein &lt; 3 g/dL</li>
<li>Bone marrow plasma cells &lt;10%</li>
<li>Absence of end-organ damage (CRAB criteria):
<ul>
<li>Hypercalcemia</li>
<li>Renal insufficiency</li>
<li>Anemia</li>
<li>Bone lesions</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Epidemiology:</strong> Common, especially in older adults</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Unknown cause</li>
<li>Thought to be a premalignant condition with a low risk of progression to multiple myeloma or other lymphoid malignancies</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Typically asymptomatic</li>
<li>Usually discovered incidentally during routine blood tests</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>Serum Protein Electrophoresis (SPEP): Small monoclonal spike (M protein)</li>
<li>Serum Immunofixation Electrophoresis (IFE): Confirms the presence and type of M protein (IgG, IgA, IgM, etc.)</li>
<li>Serum Free Light Chain (FLC) Assay: May be normal or show a slightly elevated kappa/lambda ratio</li>
<li>CBC, Renal Function Tests, Calcium Level: Normal</li>
<li>Bone Marrow Aspiration and Biopsy: Not typically required for diagnosis, but may be performed to rule out other disorders</li>
</ul>
</li>
<li>
<strong>Management:</strong>
<ul>
<li>No treatment is required</li>
<li>Periodic monitoring with SPEP, IFE, and serum FLC assay to assess for progression to multiple myeloma or other malignancies</li>
<li>Risk of Progression: Approximately 1% per year progress to multiple myeloma or other related disorders</li>
</ul>
</li>
</ul>
</div>
<div id="key-terms-33" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-33"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Plasma Cell Dyscrasia:</strong> A disorder characterized by abnormal proliferation of a single clone of plasma cells</li>
<li>
<strong>Monoclonal Gammopathy:</strong> The presence of a monoclonal immunoglobulin (M protein) in the serum or urine</li>
<li>
<strong>M Protein:</strong> A monoclonal immunoglobulin produced by the abnormal clone of plasma cells</li>
<li>
<strong>MGUS (Monoclonal Gammopathy of Undetermined Significance):</strong> Benign condition with low levels of M protein and no end-organ damage</li>
<li>
<strong>Multiple Myeloma (MM):</strong> Malignant plasma cell disorder with M protein, bone marrow involvement, and end-organ damage</li>
<li>
<strong>Bence Jones Protein:</strong> Free light chains in the urine</li>
<li>
<strong>Lytic Lesions:</strong> “Punched-out” lesions in bones seen on X-ray</li>
<li>
<strong>CRAB Criteria:</strong> Hypercalcemia, Renal insufficiency, Anemia, Bone lesions (used to define end-organ damage in myeloma)</li>
<li>
<strong>Serum Protein Electrophoresis (SPEP):</strong> A test that separates proteins in the serum based on their electrical charge</li>
<li>
<strong>Immunofixation Electrophoresis (IFE):</strong> A test that identifies the type of M protein (IgG, IgA, IgM, etc.)</li>
<li>
<strong>Autologous Stem Cell Transplant:</strong> Stem cells are collected from and transplanted to the same person</li>
</ul>
</div>
</div>
  <div class="chapter-nav">
<div class="prev"><a href="chronic-t-cell.html">Chronic T-Cell</a></div>
<div class="next"><a href="plt-production.html">PLT Production</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#plasma-cell">Plasma Cell</a></li>
<li><a class="nav-link" href="#overview-of-plasma-cell-dyscrasias"><span class="header-section-number">2.1</span> Overview of Plasma Cell Dyscrasias</a></li>
<li><a class="nav-link" href="#multiple-myeloma-mm">Multiple Myeloma (MM)</a></li>
<li><a class="nav-link" href="#monoclonal-gammopathy-of-undetermined-significance-mgus">Monoclonal Gammopathy of Undetermined Significance (MGUS)</a></li>
<li><a class="nav-link" href="#key-terms-33">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Hematology/blob/main/02-15-leukocyte-neoplasia-lymphoid-plasma.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Hematology/edit/main/02-15-leukocyte-neoplasia-lymphoid-plasma.Rmd">Edit this page <i class="fab fa-github"></i></a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-02-20 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
